Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.

Abstract: Methods, apparatus, systems, and articles of manufacture are disclosed to determine unique audience size via clustered data. An example apparatus includes memory, machine readable instructions, and processor circuitry to at least one of execute or instantiate the machine readable instructions. The example processor circuitry is to form a first matrix identifying matching and non-matching instances of first values of respective demographics of an audience of media and second values of the respective demographics. Also, the processor circuitry is to normalize the first matrix to generate an account sharing adjustment matrix. Additionally, the processor circuitry is to apply the account sharing adjustment matrix to a vector of one or more counts of impressions of the media to correct for one or more members of the audience that share a user account registered with a database proprietor, the one or more counts of the impressions corresponding to the respective demographics.

Abstract: Disclosed herein are system, method, and computer program product embodiments for performing in-flight transformations of data streams. Complex event processing (CEP) operating on event records from various data streams can operate by storing the streamed event record data in a database, and then querying the data to perform a data transformation. However, in order to improve the performance of the data transformations and streamline CEP, a serverless architecture is introduced that can perform data transformations directly on streams, using attributes of the streamed record data defined in a schema. The resulting transformed data can then be provided by the serverless architecture to the CEP for direct access of the data most needed by the CEP.

Abstract: A casing or case assembly for a mobile communications device case provides a primary device-receiving body formation. At the posterior portions of the primary device-receiving body formation is an accessory access window. The accessory access window is configured to allow a user to interface a charging device with the mobile communications device as received in the primary device-receiving body formation in anterior adjacency to an optional posterior panel portion. The accessory access window is of sufficient dimension to receive a charger device with a device diameter that fits within the window. A number of accessories, in addition to a charger device, are attachable to the mobile communications device via the accessory access window. Certain exemplary accessories include a cover panel, a wallet accessory, and a vehicular mount mechanism. At least one secondary body formation may be affixed to the primary device-receiving body formation as an outer skin thereof.

Abstract: Tamper-proof gateways are described. A gateway comprises a date intake module, a data transmission module, a tamper switch and a controller. The data intake module couples to one or more data generation devices. The data transmission module is configured to transmit sense information generated by the one or more data generation devices to a network. The tamper switch is configured to generate an alert signal in response to sensing tampering of the tamper-proof gateway. The controller is configured to: 1) place the tamper-proof gateway in a secure state in response to receiving the alert signal from the tamper switch, and 2) withdraw the tamper-proof gateway from the secure state in response to receiving authentication information. Withdrawing the gateway from the secure state may comprise placing the tamper-proof gateway in a first privileged state or a second privileged state.

Abstract: A method is presented for graphically displaying aviation emissions information. The method comprises receiving a global database comprising flight parameters for a plurality of flights over a time period, the flight parameters including at least aviation emissions information for each of the plurality of flights. Aspects of the aviation emissions information are graphically displayed on a display device based on a default model. One or more modeling strategies for reducing aviation emissions over time are presented on the display device via a graphic user interface (GUI). User input indicating input values for one or more strategic parameters of the one or more modeling strategies is received via the GUI. The strategic parameters are applied to the global database to generate modeled emissions information. The graphical display of aspects of the aviation emissions information is adjusted based on the modeled emissions information.

Abstract: The technology described herein determines whether a candidate text is in a requested class by using a generative model that may not be trained on the requested class. The present technology may use of a model trained primarily in an unsupervised mode, without requiring a large number of manual user-input examples of a label class. The may produce a semantically rich positive example of label text from a candidate text and label. Likewise, the technology may produce from the candidate text and the label a semantically rich negative example of label text. The labeling service makes use of a generative model to produce a generative result, which estimates the likelihood that the label properly applies to the candidate text. In another aspect, the technology is directed toward a method for obtaining a semantically rich example that is similar to a candidate text.

Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for the treatment of cancer characterized by TERT and BRAF mutations. In a specific embodiment, a method for treating a mutant telomerase reverse trancriptase (TERT) enzyme-associated cancer in a subject comprises the step of administering to the subject an anti-cancer agent that inhibits one or more of FOS, GABPB, the formation of the GABPA-GABPB complex or the binding of the GABPA-GABPB complex to a mutant TERT promoter.

Abstract: The present disclosure is related to processes for preparing baricitinib, salts thereof, and related synthetic intermediate compounds and salts thereof.

Abstract: This relates to an additive manufacturing method for producing a three-dimensional component made of glass, the method including the steps of: feeding continuously a glass filament having a flame retardant or self-extinguishing protective film applied to the surface thereof, from a filament feeding nozzle to a heating source for removing the flame retardant or self-extinguishing protective film and softening the glass fiber, applying the softened glass filament to a surface of a substrate or object, wherein the flame retardant or self-extinguishing protective film is made of polyimide-based material having a thickness in the range of 1 ?m to 50 ?m, wherein the fed glass filament length is less than 5 millimeters. The invention is also related to a glass filament and the use of the same.

Abstract: The present disclosure provides pharmaceutical compositions for delivery of viral antigens (e.g., a viral vaccine) and related technologies (e.g., components thereof and/or methods relating thereto).

Abstract: Artifact life tracking storage techniques include performing an artifact request of an artifact at an artifact storage node. A current time to live (TTL) value is identified. A determination is made whether to increment a TTL flag of the artifact. Responsive to determining that the TTL tag should be incremented, the TTL flag is incremented to a subsequent value in a TTL extender list. Responsive to incrementing the TTL tag, the TTL modified tag value is set to the current time value.

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Abstract: Disclosed herein is a personal care composition. In particular, disclosed herein is a substantially anhydrous personal care composition comprising at least one non-volatile emollient oil having a boiling point of at least 215° C. at atmospheric pressure, a lipophilic material, and less than 25% antiperspirant active by weight of the composition, wherein the composition has reduced volatile silicones, and further wherein the composition is substantially free of emulsifier. The disclosed personal care composition is especially useful as an efficacious antiperspirant or deodorant stick with reduced volatile silicone content that provides parity payout and sensory benefits upon topical application to skin.

Abstract: Example data transmission methods and apparatus are described. One example method includes: An access point sends first indication information to a first station, where the first indication information indicates that the first station is accepted to obtain sensing information of a second station. The access point sends the sensing information of the second station to the first station, where the access point is a proxy of the first station, the proxy is configured to obtain the sensing information of the second station for the first station, the first station is a sensing by proxy (SBP) requesting station, and the second station is a SBP responding station.

Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R6, X1, and X2 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: A system, method, and computer-readable medium for determining a root cause for a failure event. A failure of a product or system triggers a failure event. When the failure event is triggered, querying by one or more ML/DL path root cause engines is performed on stored failure incident data sets. The queried failure incident data sets are listed and ranked. Based on the ranking, a root cause is determined as to the failure event.

Abstract: A microwave includes an external enclosure having a top surface that defines a cooling air inlet and a cooling air outlet along a front edge thereof. An internal enclosure defines a cooking cavity within the external enclosure. A sidewall of the internal enclosure defines a first air passage, and a top wall of the internal enclosure defines a second air passage. A cooking component area is defined between the internal enclosure and the external enclosure adjacent the sidewall of the internal enclosure. A cooling fan is disposed within the cooking component area. The cooling fan is configured to direct air along a cooling air path from the cooling air inlet, through the cooking component area, through the cooking cavity, and to the cooling air outlet.